These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11769362)

  • 1. [Can we afford good cholesterol lowering therapy? Budgeting of statin costs versus medical needs in the county of Stockholm].
    Wettermark B; Hjemdahl P
    Lakartidningen; 2001 Nov; 98(48):5472-3, 5476-8, 5481-3. PubMed ID: 11769362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of lipid lowering in patients with coronary artery disease by case method learning.
    Kiessling A; Zethraeus N; Henriksson P
    Int J Technol Assess Health Care; 2005; 21(2):180-6. PubMed ID: 15921057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of cardiovascular disease prevention: a graded list as aid to the rational distribution of resources].
    Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE
    Lakartidningen; 1999 Jun; 96(23):2858-63, 2865-6. PubMed ID: 10405534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Broader indication for treatment with statins; the 'heart protection study'].
    Stalenhoef AF; Stuyt PM
    Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1921-3. PubMed ID: 12404905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V; Nash A; Barry M
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
    Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
    Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001.
    Tonstad S; Rosvold EO; Furu K; Skurtveit S
    J Intern Med; 2004 Apr; 255(4):494-502. PubMed ID: 15049884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
    Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
    Carrington M; Stewart S
    Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human and economic costs of undertreatment with statins.
    Durrington P
    Int J Clin Pract; 2002 Jun; 56(5):357-68. PubMed ID: 12137445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden.
    Johansson P; Ostenson CG; Hilding AM; Andersson C; Rehnberg C; Tillgren P
    Int J Technol Assess Health Care; 2009 Jul; 25(3):350-8. PubMed ID: 19619354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.